Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a biologics license application (BLA) for the full approval of Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy. What To Know: Capricor said it determined its intent to file a BLA following recent meetings with the U.S. Food and Drug Administration. Based on those meetings, Capricor plans to commence the filling in October, seeking full approval of deramiocel for the treatment of DMD-cardiomyopathy with full submission expected by the end of the year. T…